His Excellency and the delegation visited Bharath Biotech and were welcomed by Padma Bhushan holder Dr. Krishna Ella, Chairman & Managing Director and his daughter Dr. Jhalla Ella, who is a dermatologist by profession.
Being the founder of India’s indigenous lifesaving COVID-19 vaccine; COVAXIN, Dr. Ella shared his experiences in proving this vaccine to this world in versus of other vaccines. They held deliberations on how to introduce India to the Korean market. Dr. Ella stated all the problems he had to face in taking his vaccines (including ROTAVAC) to other countries.
Dr. Ella also mentioned the unique qualities of the vaccines developed at BBIL such as its ability to be used safely for all age groups and the vaccine drops can be used within 28 days of opening it.
According to Dr. Ella, he and his team are always keen to work on research that helps find sources of impending diseases and the best possible way to eradicate it. One of their achievements was to eradicate tuberculosis from our country, India.
Dr. Ella’s stressed on his dedication to creating vaccines that are not only efficient but also avoid any adverse reactions. He stated that Bharat Biotech International Limited has adopted an organisation-wide quality policy to produce pure, safe and effective high-quality biologicals and bio-therapeutics through recombinant DNA and other technologies in its goal of creating a healthier tomorrow and is committed to implementing and executing quality assurance and control policies in accordance with international requirements.